Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Gerresheimer makes the glass vials, plastic bottles, syringes, and injection pens that drug companies use to package and deliver medicines.
Gerresheimer makes the everyday containers and devices that hold and deliver medicine. If you have ever gotten a shot, used an inhaler, or taken a pill from a blister pack, there is a decent chance the packaging or the device came from this German company. It sells to drugmakers, biotech firms, and healthcare companies, and it makes money by supplying them with the physical hardware their products need — the vials, bottles, syringes, and pens that most patients never think about.
The business splits into two main parts. One makes packaging: glass vials and ampoules for injectable drugs, plus plastic bottles and blister packs for pills and liquids. The other makes drug delivery devices: prefilled syringes, injection pens, and inhalers. The packaging side is steady and dependable, while the device side is where the real growth is, especially as more medicines — particularly injectable biologics — move out of hospitals and into patients' homes. A drug company picks Gerresheimer because its products must meet strict safety and sterility standards, and once a medicine is approved with a particular container or device, switching suppliers means redoing costly regulatory work. That creates sticky, long-term relationships. The interesting shift is that Gerresheimer is no longer just a container maker. It increasingly builds the delivery device itself — the autoinjector a patient clicks against their thigh, or the pen that dials a dose. That moves it closer to being a partner in the drug, not just a supplier of glass. It is spending heavily on new plants and capacity to capture demand for injectable and biologic medicines, which is a bet that these therapies keep growing.
The risks are real. It carries a lot of debt from its expansion, and its fortunes are tied to the pharma industry's spending cycles — when drugmakers cut back or a big customer delays a launch, Gerresheimer feels it. Competition comes from other packaging and device specialists, and glass has its own supply and energy cost pressures. Still, the core logic is simple: as long as the world keeps making complex medicines, someone has to make the safe, precise containers and devices that get them into patients — and that is Gerresheimer's business.
Saved answer · last researched 15 Nov 2026